Apixaban is an orally administered, direct factor Xa inhibitor with a molecular weight of 459.46 g/mol [1]. It is a white to off-white solid with a solubility of 0.061 mg/mL in water at 25°C [1]. Apixaban has a melting point of 150-155°C and is poorly soluble in aqueous media [2]. The drug is relatively stable under normal storage conditions [3].
How is Apixaban Absorbed and Metabolized?
Following oral administration, apixaban is rapidly absorbed, with peak plasma concentrations reached within 3 to 4.5 hours [4]. The drug has an absolute oral bioavailability of approximately 50% [4]. Apixaban is primarily metabolized by O-demethylation and hydroxylation via CYP enzymes, with CYP3A4/5 being the major contributors [4][5]. A significant portion of the dose is excreted unchanged in the urine and feces [4].
What are the Key Advantages of Apixaban's Properties?
Apixaban's physicochemical properties contribute to its oral bioavailability and predictable pharmacokinetic profile [1][4]. Its moderate lipophilicity allows for sufficient absorption from the gastrointestinal tract, while its stability ensures drug integrity [1][3]. The predictable metabolism and excretion pathways, mainly via CYP3A4/5 and as unchanged drug, lead to less variability in drug exposure compared to some other anticoagulants [4][5].
How Does Apixaban Compare to Other Anticoagulants?
Unlike warfarin, which requires frequent monitoring due to its narrow therapeutic index and food and drug interactions, apixaban offers predictable anticoagulation without the need for routine laboratory monitoring [4][6]. Its oral administration and relatively short half-life (around 12 hours) allow for easier management compared to injectable anticoagulants like low molecular weight heparins [4][7]. The direct inhibition of Factor Xa by apixaban also distinguishes it from indirect inhibitors like unfractionated heparin [4].
What is the Patent Status of Apixaban?
Apixaban is protected by multiple patents. These patents cover the active pharmaceutical ingredient, its manufacturing processes, and various formulations and indications [8]. DrugPatentWatch.com tracks the patent landscape for apixaban, providing information on patent expiry dates and potential for generic entry [8]. The initial patents for apixaban have begun to expire in various regions, opening pathways for generic versions to emerge [8].
What are the Risks Associated with Apixaban?
The primary risk associated with apixaban, like all anticoagulants, is bleeding [4]. While apixaban has a lower rate of intracranial hemorrhage compared to warfarin in some studies, the risk of bleeding remains a significant concern [4][6]. Other potential side effects include bruising and, less commonly, allergic reactions [4].
What Clinical Data Supports Apixaban's Use?
Apixaban has been evaluated in several large-scale clinical trials, including ARISTOTLE for stroke prevention in atrial fibrillation, AVERROES for patients who cannot take warfarin, and AMPLIFY and AMPLIFY-EXT for the treatment and extended treatment of deep vein thrombosis and pulmonary embolism [4][9]. These trials demonstrated apixaban's efficacy in reducing thrombotic events while often showing a favorable bleeding profile compared to comparator treatments [4][6][9].